Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) [Phase 2]

View source ↗

Summary

A Phase 2 trial (BUOY-1) is evaluating the efficacy and safety of SPT-300 (GlyphAllo) for major depressive disorder with or without anxious distress; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Major Depressive Disorder with Anxious Distress

Drugs mentioned

• SPT-300 (GlyphAllo) (GlyphAllo)

Snippet

Sponsor: Seaport Therapeutics | Conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | Phase 2 | Status: RECRUITING